SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| BYETTA 10 mcg/ml solution for injection pre-filled pen | 10 µ/ml | Solution for injection · Subcutaneous use | 1 Pre-filled pen | SAR 235.95 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| BYETTA 250 MCG/ML PRE - FIIED PEN | 250 µ/ml | Injection · Subcutaneous use | 1 Pre-filled pen | SAR 511.30 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| BYETTA 250 MCG/ML PRE - FIIED PEN | 250 µ/ml | Injection · Subcutaneous use | 1 Pre-filled pen | SAR 511.30 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| BYETTA 250 MCG/ML PRE - FIIED PEN | 250 µ/ml | Injection · Subcutaneous use | 1 Pre-filled pen | SAR 511.30 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| BYETTA 250 MCG/ML PRE - FIIED PEN | 250 µ/ml | Injection · Subcutaneous use | 1 Pre-filled pen | SAR 511.30 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| BYETTA 5 mcg/ml solution for injection pre-filled pen | 5 µ/ml | Solution for injection · Subcutaneous use | 1 Pre-filled pen | SAR 165.15 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
EMA European Union — centrally authorised medicines
Byetta AstraZeneca AB · Withdrawn · authorised 20 Nov 2006 · ATC A10BJ01
Therapeutic indication (EMA)
Byetta is indicated for treatment of type-2 diabetes mellitus in combination with: metformin; sulphonylureas; thiazolidinediones; metformin and a sulphonylurea; metformin and a thiazolidinedione; in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.
Bydureon AstraZeneca AB · Withdrawn · authorised 17 Jun 2011 · ATC A10BJ01
Therapeutic indication (EMA)
Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations). Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with: Metformin Sulphonylurea Thiazolidinedione Metformin and sulphonylurea Metformin and thiazolidinedione in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | EXENATIDE 10 MCG DOSE PEN INJ | $300.1675 | per ML | 22 Jul 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.